SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs)

被引：0
|
作者：
Paluch, Peter [1 ]
Sterclova, Martina [1 ]
Brabcova, Irena [2 ]
Viklicky, Ondrej [2 ]
Vasakova, Martina [1 ]
机构：
[1] Thomayer Hosp, Dept Resp Med, Prague 4, Czech Republic
[2] Inst Clin & Expt Med, Dept Nephrol, Prague, Czech Republic
来源：
EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷
关键词：
Interstitial lung disease; Immunology; Experimental approaches;
D O I：
10.1183/13993003.congress-2015.PA934
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA934
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effects of Nintedanib on Circulating Biomarkers in Subjects with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
    Maher, T. M.
    Jenkins, R. G.
    Bonella, F.
    Assassi, S.
    Diefenbach, C.
    Ittrich, C.
    Rohr, K. B.
    Kolb, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [2] HEALTHCARE RESOURCE UTILIZATION AND RELATED COSTS IN PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS)
    Olson, A.
    Hartmann, N.
    Patnaik, P.
    Garry, E.
    Bohn, R.
    Singer, D.
    Baldwin, M.
    Wallace, L.
    VALUE IN HEALTH, 2020, 23 : S353 - S353
  • [3] Efficacy and Safety of Nintedanib in Elderly Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs)
    Moua, T.
    Bonella, F.
    Okamoto, M.
    Tomassetti, S.
    Valenzuela, C.
    Wuyts, W.
    Miede, C.
    Lievens, D.
    Bendstrup, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [4] Impact of weight loss on outcomes in patients with progressive fibrosing interstitial lung diseases (ILDs)
    Kreuter, M.
    Bendstrup, E.
    Maher, T. M.
    Inoue, Y.
    Miede, C.
    Lievens, D.
    Crestani, B.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [5] Smoking and interstitial lung diseases(ILDs)
    Puscinska, Elzbieta
    Goljan-Geremek, Anna
    Radzikowska, Elzbieta
    Wyrostkiewicz, Dorota
    Nowinski, Adam
    Bednarek, Michal
    Sliwinski, Pawel
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [6] Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*
    Bonella, Autoren F.
    Moua, T.
    Okamoto, M.
    Tomassetti, S.
    Valenzuela, C.
    Wuyts, W.
    Miede, C.
    Lievens, D.
    Bendstrup, E.
    PNEUMOLOGIE, 2023, 77 : S57 - S57
  • [7] Characteristics of Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) in the INBUILD Trial of Nintedanib
    Flaherty, K. R.
    Wells, A. U.
    Clerisme-Beaty, E.
    Cottin, V.
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S.
    Goeldner, R.
    Schlenker-Herceg, R.
    Brown, K. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [8] CHARACTERISTICS OF PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS) IN THE ILD-PRO REGISTRY
    Lobo, Leonard
    Liu, Yi
    Li, Peide
    Ramaswamy, Murali
    Swaminathan, Aparna
    Veeraraghavan, Srihari
    Fan, Yanni
    Neely, Megan L.
    Palmer, Scott M.
    Olson, Amy L.
    CHEST, 2023, 164 (04) : 3056A - 3057A
  • [9] Upper Lobe Predominant Fibrosing Interstitial Lung Diseases (ILDs): Prevalence, Causes, Characteristics and Prognosis
    Nunes, H.
    Mourtada, L.
    Sese, L.
    Brillet, P.
    Bouvry, D.
    Kambouchner, M.
    Valeyre, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [10] Diagnostic Delays in Interstitial Lung Diseases (ILDs)
    Wijsenbeek, M.
    Deparis, N.
    Valenzuela, C.
    Orsatti, L.
    Mounir, B.
    Danoff, S. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345